Jul 20, 2020 | Video Transcripts
Expert pharmacists provide community physicians with recommendations for optimizing success on treatment for patients with chronic lymphocytic leukemia (CLL). Alison Duffy, PharmD, BCOP: What are your recommendations, Dr Steeves, for physicians in the community to...Jul 17, 2020 | Video Transcripts
Key opinion leaders discuss which characteristics of oral therapies need to be managed by pharmacists. Alison Duffy, PharmD, BCOP: We talked a little bit about the efficacy and safety information. What characteristics of the oral therapies that we haven’t...Jul 17, 2020 | Video Transcripts
A comparison of the safety and efficacy of orally and intravenously administered oncolytics. Alison Duffy, PharmD, BCOP: Dr Steeves, what has been your experience with efficacy and safety of the oral agents versus IV [intravenous] in terms of best practices for...Jul 16, 2020 | Video Transcripts
Key opinion leaders discuss trials focusing on patient populations with newly diagnosed chronic lymphocytic leukemia (CLL). Alison Duffy, PharmD, BCOP: I’d love to hear your thoughts on other treatment options besides ibrutinib in a newly diagnosed setting and...Jul 16, 2020 | Video Transcripts
Experts in the field of chronic lymphocytic management (CLL) consider how MRD (minimum residual disease) testing affects the use of limited duration therapy. Alison Duffy, PharmD, BCOP: What are your thoughts on the limited duration of therapy based on some of the...